Rebecca L. Anderson

Array ( [id] => 20279365 [patent_doc_number] => 20250304607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-02 [patent_title] => PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 19/236398 [patent_app_country] => US [patent_app_date] => 2025-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19236398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20226314 [patent_doc_number] => 12414954 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => POLQ inhibitors [patent_app_type] => utility [patent_app_number] => 19/072385 [patent_app_country] => US [patent_app_date] => 2025-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97008 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19072385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20085007 [patent_doc_number] => 20250214943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-03 [patent_title] => Compounds [patent_app_type] => utility [patent_app_number] => 19/002491 [patent_app_country] => US [patent_app_date] => 2024-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19002491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20329699 [patent_doc_number] => 12459965 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use [patent_app_type] => utility [patent_app_number] => 18/989682 [patent_app_country] => US [patent_app_date] => 2024-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 32 [patent_no_of_words] => 26990 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18989682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543126 [patent_doc_number] => 20240360162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 18/767494 [patent_app_country] => US [patent_app_date] => 2024-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18767494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528130 [patent_doc_number] => 20240352032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/753212 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18753212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528082 [patent_doc_number] => 20240351984 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => INDOLINE COMPOUNDS FOR INHIBITING KIF18A [patent_app_type] => utility [patent_app_number] => 18/735162 [patent_app_country] => US [patent_app_date] => 2024-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18735162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20143939 [patent_doc_number] => 12378266 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders [patent_app_type] => utility [patent_app_number] => 18/678114 [patent_app_country] => US [patent_app_date] => 2024-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 29243 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18678114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256068 [patent_doc_number] => 12428411 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/672808 [patent_app_country] => US [patent_app_date] => 2024-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26439 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18672808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19769902 [patent_doc_number] => 20250051328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => SALTS OF AN FGFR INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/671458 [patent_app_country] => US [patent_app_date] => 2024-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23816 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18671458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448841 [patent_doc_number] => 20240308971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => ALLOSTERIC INHIBITOR OF WEE1 KINASE [patent_app_type] => utility [patent_app_number] => 18/668678 [patent_app_country] => US [patent_app_date] => 2024-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19249 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18668678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846660 [patent_doc_number] => 20250092011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => Crystalline Forms Of An Androgen Receptor Modulator [patent_app_type] => utility [patent_app_number] => 18/662345 [patent_app_country] => US [patent_app_date] => 2024-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18662345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20607066 [patent_doc_number] => 12582645 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-24 [patent_title] => Chemokine CXCR4 receptor modulators and uses related thereto [patent_app_type] => utility [patent_app_number] => 18/655194 [patent_app_country] => US [patent_app_date] => 2024-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69969 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18655194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20187041 [patent_doc_number] => 12398146 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Heterobicyclic amides as inhibitors of CD38 [patent_app_type] => utility [patent_app_number] => 18/638989 [patent_app_country] => US [patent_app_date] => 2024-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 27 [patent_no_of_words] => 59263 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20213551 [patent_doc_number] => 12410193 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Bicyclic heterocyclyl derivatives as IRAK4 inhibitors [patent_app_type] => utility [patent_app_number] => 18/629313 [patent_app_country] => US [patent_app_date] => 2024-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35412 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18629313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281455 [patent_doc_number] => 20240217929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => SYNTHESIS OF N,N-DIMETHYLTRYPTAMINE-TYPE COMPOUNDS, METHODS, AND USES [patent_app_type] => utility [patent_app_number] => 18/602171 [patent_app_country] => US [patent_app_date] => 2024-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18602171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20007414 [patent_doc_number] => 20250145636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => PROTEIN DEGRADERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/602701 [patent_app_country] => US [patent_app_date] => 2024-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18602701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528132 [patent_doc_number] => 20240352034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS [patent_app_type] => utility [patent_app_number] => 18/588051 [patent_app_country] => US [patent_app_date] => 2024-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379234 [patent_doc_number] => 20240269104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => METHOD FOR TREATING PARKINSON'S DISEASE [patent_app_type] => utility [patent_app_number] => 18/444049 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556357 [patent_doc_number] => 20240368149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => ANALOGS OF XANOMELINE [patent_app_type] => utility [patent_app_number] => 18/444450 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444450 [rel_patent_id] =>[rel_patent_doc_number] =>)